ACADIA Pharmaceuticals

$54.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.88 (+1.63%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell ACAD and other stocks, options, and ETFs commission-free!

About ACAD

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. The listed name for ACAD is ACADIA Pharmaceuticals Inc. Common Stock.

CEO
Stephen R. Davis
Employees
503
Headquarters
San Diego, California
Founded
1993
Market Cap
8.70B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.08M
High Today
$54.84
Low Today
$53.53
Open Price
$54.07
Volume
1.11M
52 Week High
$58.72
52 Week Low
$30.02

Collections

ACAD Earnings

-$0.59
-$0.39
-$0.20
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 24, After Hours

You May Also Like